COMPARISON OF PATIENTS AND PSYCHIATRISTS EXPECTATIONS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER – EXPECTA STUDY

Authors

DOI:

https://doi.org/10.16891/2317-434X.v12.e3.a2024.pp4402-4411

Keywords:

survey, quality of life, desvenlafaxine

Abstract

Major depressive disorder (MDD) is highly prevalent in Brazil, yet no data exists comparing treatment expectations of Brazilian psychiatrists and patients. This study aims to assess and contrast these expectations while exploring potential sociodemographic and clinical influencers. We conducted a cross-sectional online survey to comprehend the expectations surrounding antidepressant drug treatments for both psychiatrists and patients. Our survey garnered participation from 502 patients and 112 psychiatrists, with the majority being female. Most respondents from both groups were affiliated with private healthcare services. Desvenlafaxine emerged as the most frequently used medication. Comparing expectations between psychiatrists and patients, physician ratings predominately leaned towards 4 (high) and 5 (very high/total), particularly in the domains of core depression symptoms and quality of life and functionality. Among patients, responses in these domains mainly clustered around 3 (average) and 4 (high). In conclusion, psychiatrists demonstrated greater expectations for antidepressant medications in ameliorating MDD, with emphasis on quality of life/functionality and anhedonia.

Author Biographies

Guilherme Cruz, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Master in Pharmaceutical Science and Technology from UFRJ (2023). Graduated in Pharmacy from the Federal University of Rio de Janeiro (2017) and Pharmacy Technician from IFRJ (2009). With experience in the Pharmaceutical Industry since 2013, he worked as a Medicines Representative in the area of ​​antidepressant medicines (2016 - 2022) and assumed the position of Medical Science Liaison (MSL) in the area of ​​Cardiology, by the French multinational Servier (05.2022 - to present) .

Milene da Costa, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Adjunct professor at the Faculty of Pharmacy of the Federal University of Rio de Janeiro, Master of Science in Biomedical Engineering from the Biomedical Engineering Program at COPPE/UFRJ and PhD in Biological Sciences/Biophysics from the Carlos Chagas Filho Institute of Biophysics/UFRJ. She has a postdoctoral degree in Health Economic Assessments carried out at the Istituto di Ricerche Farmacologiche Mario Negri-Italy. Professor of the Professional Master's Program in Health Technology Assessment at the National Institute of Cardiology. She works in the areas of Health Technology Assessment, Health Economic Assessment, Technological Horizon Monitoring and Applied Statistics. She is coordinator of the Center for Economic Assessment of Health Technologies-NECTES / UFRJ. Member of the Brazilian Health Technology Assessment Network (REBRATS). Member of the Health Technological Assessment Center at the UFRJ Hospital Complex. Member of the Health Technology Assessment Center at the National Institute of Cardiology.

Luiz da Silva, Faculty of Pharmacy, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil

Graduated in Pharmacy from the Federal University of Rio de Janeiro (2007). Specialist in Pharmaceutical Industrial Technology from UFRJ (2010). PhD in Pharmaceutical Sciences from the Postgraduate Program in Pharmaceutical Sciences at the Faculty of Pharmacy at UFRJ (2012). Sandwich PhD internship at the Universitá Degli Studi di Pavia (Italy - 2011-2012), Post-doctoral internship at the Laboratory of Pharmaceutical Industrial Technology (LabTIF) (2012 - 2013), Professor 40 hours (DE) at the Faculty of Pharmacy of UFRJ (2013 - current). Young Scientist of Our State (JCNE 2020), member of the Innovation and Entrepreneurship Center of the Faculty of Pharmacy/UFRJ and the Biosafety Chamber of the Health Sciences Center of UFRJ. He works in teaching and research in the following areas: 1) Synthesis, characterization and evaluation of the efficacy and safety of therapeutic and/or diagnostic nanosystems. 2) Development and evaluation of pharmaceutical forms and in vitro, ex vivo and in vivo evaluation. 3) Pharmaceutical Quality Management. 4) Innovation and entrepreneurship.

Downloads

Published

2024-11-10

How to Cite

Silva Cruz, G., Rangel da Costa, M., & da Silva, L. C. (2024). COMPARISON OF PATIENTS AND PSYCHIATRISTS EXPECTATIONS IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER – EXPECTA STUDY. Revista Interfaces: Saúde, Humanas E Tecnologia, 12(3), 4402–4411. https://doi.org/10.16891/2317-434X.v12.e3.a2024.pp4402-4411

Issue

Vol. 12 No. 3 (2024):

Section

Artigos